AstraZeneca Likes Sound Of Silence's Science
UK Biotech Gets $80m Upfront
The UK major is getting access to Silence's small interfering RNA (siRNA) platform while the London-based biotech is getting further validation of its technology and a considerable pile of cash.
You may also be interested in...
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
The gene silencing specialist has signed a collaboration that CEO David Horn Solomon tells Scrip will help push Silence up among its peers in the RNAi space.
The diagnostics tie-up with GSK on testing is a near-term move to help the UK get back to normality, the drug major's biopharmaceuticals R&D boss tells Scrip. AstraZeneca's main focus is to develop monoclonal antibodies to tackle 'wave two' of the coronavirus.